Ionis Poised To Build Out Commercial Portfolio With Donidalorsen Success

A Phase III study testing the ligand-conjugated anti-sense medicine in hereditary angioedema read out positively, but the drug would join a competitive market if approved.

soccer goal
Ionis has had sequential positive data read outs • Source: Shutterstock

Ionis Pharmaceuticals, Inc. is on track for back-to-back drug launches after announcing positive Phase III data on its ligand-conjugated anti-sense (LICA) medicine donidalorsen as a prophylactic treatment for hereditary angioedema (HAE), which Ionis could submit for US Food and Drug Administration approval soon after it submits olezarsen for familial chylomicronemia syndrome (FCS).

The company announced positive data from the Phase III OASIS-HAE study of donidalorsen on 22 January and said it is...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Takeda Prepares Ground For Oveporexton In Narcolepsy

 

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.

Leo Lands Another Big Pharma Pact With Boehringer Spevigo Deal

 
• By 

Paying €90m upfront for rights to generalized pustular psoriasis drug.

Pipeline Watch: Ten Approvals And Two Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Capricor Gets Complete Response For DMD Cell Therapy

 
• By 

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.

More from R&D